Aerial view of the Bay Bridge in San Francisco, CA

Join EY-Parthenon on January 13, 2026 at the 2026 McDermott Forum in San Francisco

EY-Parthenon is the Knowledge Partner Sponsor at the McDermott Forum during Healthcare Conference week

We invite you to join us and/or schedule a one-on-one meeting at a dedicated space to discuss your unique challenges and explore tailored solutions that can drive your success.


Join EY, McDermott Will & Schulte, and other top industry leaders for a lively program featuring diverse voices in the sector and investor community as they discuss industry trends, innovation, regulatory change and the sector outlook in 2026.

January 13, 2026 - Program overview

Cross-border biopharma: How pricing, policy and geopolitics are shaping 2026’s deal landscape
8:30 AM – 9:10 AM
Co-moderators: Ranu Carroll - EY-Parthenon Americas Life Sciences Leader | McDermott Will & Schulte

As global headwinds multiply, biopharma dealmaking faces a new reality — one where pricing reforms, tax pressure and shifting geopolitical alliances are increasingly driving strategy. This panel brings together US and EU leaders to unpack how policy trends and market sentiment are shaping deal flow and investment priorities across the globe. Expect a clear-eyed discussion of how companies are recalibrating transaction strategy, where capital is moving next and what 2026’s regulatory and political landscape could mean for cross-border growth.

Medtech M&A: Will 2026 finally be a breakout year?
9:10 AM – 9:50 AM
Moderator: John Babitt – EY Global MedTech Leader | McDermott Will & Schulte

The MedTech industry is entering a pivotal period of portfolio reshaping, marked by continued M&A momentum for certain industry participants and selective public-market re-openings. This panel will explore key trends shaping the sector—from the evolution of MedTech deal activity over the past decade to the current state of the IPO market and the growing role of private equity in fueling innovation and take privates. The discussion will highlight recent portfolio optimization moves as many companies continue to reposition themselves to take advantage of higher-growth end markets. Panelists will share perspectives on valuation dynamics, deal timing, and the strategic rationale driving both corporate and sponsor-led transactions, offering practical insights into where MedTech dealmaking is headed next.

Fireside chat: Innovative capital strategies in life sciences
10:05 AM – 10:35 AM
Co-moderators: Arda Ural - EY Americas Life Sciences Leader | McDermott Will & Schulte

As the life sciences sector enters a new phase of growth, capital strategies are rapidly evolving to meet new market demands. This session will explore the innovative approaches shaping the industry, and the strategic investment priorities expected to define the landscape in 2026.

Beyond compliance: How regulation is reshaping health and life sciences investments
10:35 AM – 11:15 AM
Co-moderators: Heather Meade - Principal, Washington Council, Ernst & Young LLP | McDermott Will & Schulte

Political uncertainty, shifting Food and Drug Administration (FDA) priorities and evolving global trade dynamics are increasingly dictating where and how capital flows into healthcare and life sciences. From approval timelines and supply chain resilience to funding disruptions and policy reform, regulation now sits at the center of investment and growth strategy. This panel will examine how investors and operators are underwriting regulatory risk, finding opportunities amid policy volatility and recalibrating deal theses for a more complex market. Expect an unvarnished discussion of how evolving FDA and global policy trends are driving valuations, deal pacing and innovation across the sector.

Health innovations: Creating connected, member-focused care networks
11:15 AM – 11:45 AM
Co-moderators: Deblina Ghosh - Principal, Strategy and Execution, EY-Parthenon | McDermott Will & Schulte

Stakeholders grappling with rising healthcare costs are turning to technology and new models for delivering and managing care. From breakthroughs in the pharmacy value chain to centers of excellence (COEs) and artificial intelligence (AI) solutions that enhance provider efficiency, organizations are leveraging technology to engage members and contain costs. This session will explore how emerging platforms — such as AI-powered scheduling and documentation tools and more — are driving a more connected, member-focused network of care. Join us to examine the evolving role of pharmacy, providers and AI in building the healthcare network of the future.

Fireside chat: Private equity (PE) investment trends in healthcare
11:45 AM – 12:15 PM
Co-moderators: Dan Shoenholz - EY-Parthenon Health and Life Sciences Private Equity Leader | McDermott Will & Schulte

As we enter the New Year, our professional panel will explore the evolving outlook for healthcare PE investing, highlighting the themes that present the most promising opportunities for investors. In this session, attendees will gain valuable insights into the key trends and challenges shaping the healthcare investment landscape. Whether you’re a seasoned investor or new to the industry, this fireside chat will provide you with actionable insights and a deeper understanding of the forces driving activity in healthcare PE.


Our latest thinking

Healthcare sector outlook: growing amid headwinds in 2026 

Healthcare sector leaders can unlock strategic growth in 2026 amidst economic and regulatory challenges. Learn more.

M&A outlook: stronger US deal market in 2026 despite mixed economic signals

The EY-Parthenon Deal Barometer, informed by our US economic outlook, predicts robust US deal volume growth through 2026.

Private Equity Pulse: key takeaways from Q3 2025

Private equity exits reach a three-year high as firms seize opportunities to turn strategic value creation into realized returns.

Cash management is key for hospitals facing Medicaid eligibility changes

Healthcare companies should prepare for Medicaid redeterminations challenge by improving balance sheet health and liquidity.

Hye Yu + 1

Pulse of the MedTech Industry Report

EY MedTech report on dealmaking, financing and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.

How Bristol Myers Squibb overhauled working capital to fund its future

EY-Parthenon team helped BMS establish a cash leadership office as part of an award-winning Treasury transformation. Learn more in this case study.

How proactive hospital capacity management can create financial value

Better hospital capacity management strategy can result in financial and patient care improvements and health care transformation. Learn more

Investing in innovation: unlocking value in MedTech

An analysis of value creation among MedTech sector companies underscores the pivotal role of investment in R&D as a driver of long-term value creation.

When and how to use GenAI in late-stage clinical development

Discover the impact of GenAI in clinical trials, including potentially improved trial design and streamlined regulatory processes for drug development.

Four areas of innovation can shape the future of health care value

Health care payers are thriving by tackling common operational challenges. Discover how.

How IntraBio's finance transformation fueled its global expansion

For its global expansion, IntraBio needed to solve operational and financial back-office challenges. Learn how EY finance transformation services helped.

EY Firepower report: life sciences dealmaking – trends in 2025

Learn how smaller, smarter deals will shape a confident future for life sciences.

    Connect with our leaders

    photographic potrait of john babitt

    John Babitt
    EY Global Medtech Leader

    Photographic potrait of ranu carroll

    Ranu Nandy Carroll
    Americas Life Sciences Sector Leader, Strategy & Transactions, EY-Parthenon

    Photographic potrait of kim

    Kim Dalla Torre
    EY Global & Americas Health Leader & Client Service Partner

    photographic potrait of deblina ghosh

    Deblina Ghosh
    Healthcare and Group Strategy

    photographic potrait of heather

    Heather E. Meade
    Principal, Washington Council, Ernst & Young LLP

    photographic potrait of dan

    Dan Shoenholz
    EY-Parthenon US Health and Life Sciences Private Equity Leader

    photographic potrait of arda ural

    Arda Ural
    EY Americas Life Sciences Leader


    Solutions that work in practice, not just on paper

    Learn how a pharma company’s growth and operational strategy helped establish a global footprint.


    Creating new life sciences revenue models

    Venture building can help life sciences companies drive innovation in the face of the patent cliff.